Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies

Keyphrases

• New Therapies 100%
• Influenza 100%
• Cost of Illness 100%
• Emerging Therapies 100%
• Economic Evaluation 100%
• Influenza-like Illness 80%
• Vaccination 60%
• Virus 40%
• Neuraminidase Inhibitors 40%
• Low Risk 20%
• Economic Impact 20%
• Healthcare Professionals 20%
• Clinical Practice 20%
• Influenza Virus 20%
• Clinical High Risk 20%
• Associated Complications 20%
• Harmful Effects 20%
• Preventive Measures 20%
• Humankind 20%
• Oseltamivir 20%
• Symptom Duration 20%
• Symptom-based 20%
• Infection Diagnosis 20%
• Infectious Complications 20%
• Diagnostic Challenge 20%
• Cause of Illness 20%
• Clinical Impact 20%
• Influenza Vaccine 20%
• Treatment Measures 20%
• Zanamivir 20%
• Clinical Potential 20%
• Impact Treatment 20%
• Vaccine Use 20%
• Typical Year 20%
• Clinical Controversy 20%
• Influenza Complications 20%
• Economic Perspective 20%

Nursing and Health Professions

• Influenza 100%
• Cost of Illness 100%
• Economic Evaluation 100%
• Disease 66%
• Sialidase Inhibitor 66%
• Health Care Personnel 33%
• Drug Therapy 33%
• Diagnosis 33%
• Clinical Practice 33%
• Influenza Vaccine 33%
• Oseltamivir 33%
• Flu Like Syndrome 33%
• Pandemic 33%
• Relenza 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Influenza 100%
• Sialidase Inhibitor 66%
• Oseltamivir 33%
• Influenza Virus 33%
• Flu Like Syndrome 33%
• Influenza Vaccine 33%
• Pandemic 33%
• Relenza 33%